Bristol Myers Squibb's robust pipeline and strong balance sheet support future growth and income potential. Find out what ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level. Read why I ...

The company recently received positive news with the FDA moving up the PDUFA date for subcutaneous Opdivo to December 2024, two months earlier than previously expected. Analysts anticipate ...

September saw several notable 'firsts' in the regulatory landscape alongside the approval of four novel drugs in the U.S. Among ...

That could happen by Dec. 29, when the FDA is expected to issue a verdict on an Opdivo formulation administered via an under-the-skin injection. Subcutaneous Opdivo is the product of a partnership ...

Blackstone will provide €300 million in funding for the project, which will focus on a subcutaneous formulation ... therapy with Bristol-Myers Squibb's Opdivo (nivolumab). Sarclisa is a CD38 ...

Opdivo is in an arms race with Merck & Co ... or chain of natural sugars to deliver drugs into the body via subcutaneous injection – a easier formulation than that intravenous administration ...

BMS Proposes Perioperative Opdivo Regimen in NSCLC Bristol Myers Squibb is advancing ... Zealand is developing the drug candidate as a subcutaneous continuous infusion delivered via a wearable pump ...

Bristol Myers Squibb (BMS) has received approval from the US Food and Drug Administration (FDA) for Opdivo to treat adults with resectable non-small cell lung cancer (NSCLC). These adult patients ...

Receiving perioperative Opdivo for non-small cell lung cancer showed event-free survival benefits compared with placebo. Patients with resectable (surgically unremovable) non-small cell lung cancer ...

The Food and Drug Administration has approved Opdivo before and after surgery for some with non-small cell lung cancer. The Food and Drug Administration (FDA) has approved neoadjuvant (presurgical) ...

Opdivo’s U.S. patent loss is expected in 2028, Europe in 2030, and Japan in 2031. Another cancer drug, Yervoy (ipilimumab), is expected to lose market exclusivity in 2025 in the U.S. and Japan ...